

1 **Laboratory-based surveillance of COVID-19 in the Greater Helsinki**
2 **area, Finland, February-June 2020**

3

4 Jarva H^{1,2}, Lappalainen M¹, Luomala O³, Jokela P¹, Jääskeläinen AE¹, Jääskeläinen AJ¹, Kallio-
5 Kokko H¹, Kekäläinen E^{1,2}, Mannonen L¹, Soini H³, Suuronen S¹, Toivonen A¹, Savolainen-Kopra
6 C³, Loginov R¹, Kurkela S¹

7

8 ¹HUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki
9 University Hospital, Finland

10 ²Translational Immunology Research Program and Department of Bacteriology and Immunology,
11 University of Helsinki, Helsinki, Finland

12 ³Finnish Institute for Health and Welfare (THL), Helsinki, Finland

13 **Corresponding author:** Satu Kurkela

14 **Email:** satu.kurkela@hus.fi

15 **Address:**

16 Helsinki University Hospital,

17 HUSLAB, Virology and Immunology

18 P.O.B. 720 (Topeliuksenkatu 32)

19 FIN-00029 HUS, Finland

20 **Tel: +358 9 4711**

21

22

23 **Keywords:** COVID-19; nucleic acid amplification; real-time RT-PCR; SARS-CoV-2; surveillance

24 **Conflict of interest:** None of the authors have conflict of interest.

25 **Funding statement:** Funded by Helsinki University Hospital, HUSLAB, Helsinki, Finland.

26 **Contribution:**

27 HJ: Hanna Jarva; ML: Maija Lappalainen; OL: Oskari Luomala; PJ: Pia Jokela; AEJ: Anu E.

28 Jääskeläinen, AJJ: Annemarjut J Jääskeläinen, HKK: Hannimari Kallio-Kokko; EK: Eliisa

29 Kekäläinen; LM: Laura Mannonen; HS: Hanna Soini; SS: Satu Suuronen; AT: Anne Toivonen;

30 CSK: Carita Savolainen-Kopra; RL: Raisa Loginov, SKU: Satu Kurkela

31 Conceptualisation: HJ, SKU, EK, ML. Data curation: HJ, SKU, OL. Formal analysis: HJ, SKU,

32 OL. Funding: ML. Investigation: HJ, ML, OL, AEJ, AJJ, PJ, EK, HKK, LM, HS, SS, AT, CSK,

33 RL, SKU. Methodology: HJ, ML, AEJ, PJ, HKK, LM, RL, SKU. Project administration: HJ, SKU.

34 Resources: ML. Validation: HJ, SKU, ML. Writing - original draft: HJ, SKU. Writing - review &

35 editing, HJ, ML, OL, AEJ, AJJ, PJ, EK, HKK, LM, HS, SS, AT, CSK, RL, SKU. All authors

36 approved the final version of the manuscript.

37 **Acknowledgements**

38 We would like to thank the staff at the Department of Virology and Immunology working with

39 SARS-CoV-2 diagnostics.

40

41 **Abstract**

42 Laboratory registry data (80,791 specimens, 70,517 individuals) was used to characterise age- and
43 sex-specific SARS-CoV-2 RT-PCR sampling frequency and positivity rate, and laboratory capacity
44 building in Greater Helsinki, Finland during February-June 2020. While the number of positive
45 cases was similar in males and females, the positivity rate was significantly higher in males. The
46 highest incidence/100,000 was observed in those aged ≥ 80 years. The proportion of young adults in
47 positive cases increased in late May 2020.

48

49 The WHO has advocated for the “test, trace, treat” strategy in the mitigation of COVID-19
50 pandemic [1]. Rarely has sophisticated laboratory diagnostics been set up at this pace and extent. As
51 the epidemiological situation evolved quickly, the laboratory capacity building over the past few
52 months played a key role in the epidemic response in each country. At the same time, laboratory-
53 based surveillance can provide high quality data for public health management. By using laboratory
54 registry data, the aim of this study was to characterise age- and sex-specific sampling frequency and
55 positivity rate, and to characterise laboratory capacity building of SARS-CoV-2 RT-PCR testing in
56 Greater Helsinki area in Finland during February-June 2020.

57 **Registry data**

58 This study was based on the laboratory registry database of the Helsinki University Hospital
59 Laboratory (HUS Diagnostic Center, HUSLAB), Finland. This laboratory provides services to
60 Greater Helsinki, with a population of 1,685,983 (48.8% males, 51.2% females) as per 31
61 December 2019 [2].

62 The data included the date of sampling, sex, age, and the SARS-CoV-2 RT-PCR test result on
63 specimens from 1 February to 15 June 2020. The data were collected according to permit
64 HUS/157/2020 (Helsinki University Hospital, Finland). The data were analysed with GraphPad
65 Prism[®] according to tests and individual cases. In the case analysis, only the first test of the negative
66 cases was counted. For the positive cases, only the first positive test was counted.

67 Data from the National Infectious Disease Register of the National Institute for Health and Welfare
68 (THL) were retrieved to calculate age-specific incidence.

69 **Laboratory methods**

70 The respiratory specimens were subjected to one of the following methods: a protocol based on
71 Corman et al. [3], cobas[®] SARS-CoV-2 test kit on the cobas[®] 6800 system (Roche Diagnostics,
72 Basel, Switzerland), Amplidiag[®] COVID-19 test (Mobidiag, Espoo, Finland) and Mobidiag

73 Novodiag® Covid-19 assay (Mobidiag, Espoo, Finland). The performance of these tests in our
74 laboratory is reported elsewhere [4, 5].

75 **Results**

76 Of the 86,927 specimens sent to HUSLAB for SARS-CoV-2 RT-PCR testing between 1 February
77 and 15 June 5,061 were excluded as they originated outside of Greater Helsinki. Additional 1,075
78 specimens were excluded as they gave repeatedly an invalid test result, or were never analysed due
79 to a preanalytical failure. The final data included 80,791 specimens (Figure 1a) from 70,517
80 individuals: 29,885 (37.0%) specimens from 25,948 individual males, and 50,906 (63.0%)
81 specimens from 44,569 individual females. The tested individuals had a median age of 43 years,
82 mean 45 years, and a range of 0 days - 106 years. Altogether 4,057/80,791 (5.0%) of the specimens
83 were positive, and 3,915/70,517 (5.6%) of the individuals were found positive.

84 The first positive case in Greater Helsinki was diagnosed on 25 February (Figure 1b). This was the
85 second COVID-19 case diagnosed in Finland, the first being a Chinese tourist in Lapland [6]. As of
86 9 March, both the number of tests, positive tests and cases increased rapidly (Figure 1). A peak was
87 reached on 3 April (96 new cases) (Figure 1b), and the daily number of new cases remained high
88 throughout April and early May.

89 During the epidemic peak, the daily number of tests was still increasing through rapid capacity
90 building. The daily number of tests (by sampling date) increased from 308 tests on March 15 to
91 1005 tests on April 15, and further to 1530 tests on May 15 (Figure 1a).

92 The highest proportion of positive cases was found in the age group 50-59 years (6.7%), and the
93 lowest in the age group 0-9 years (2.9%) (Figure 2a). The number of test positive cases was highest
94 in working-age adults (20-59 years) (Figure 2b). The age stratification of new positive cases over
95 time showed a shift towards an increasing proportion of young adults (20-39 years) as of late May

96 (Figure 2c). The incidence per 100,000 population in the Greater Helsinki area was 287/100,000
97 population, and highest in those aged ≥ 80 years (560/100,000) (Figure 2d).

98 In age group 0-29 years, the proportion of test positive cases peaked in weeks 13-15, while in age
99 group 30-79 years the highest proportions were observed already in weeks 11 and 12 (Figure 3). In
100 those aged ≥ 80 years, the proportion of positive cases began to increase in week 13, and peaked in
101 week 15 (Figure 3).

102 Of the positive cases, 1935/3,915 (49.4%) were males, and 1980/3,915 (50.6%) females, and they
103 had a median age of 43 years, mean 45 years, and range 0-100 years. Thus, 7.5% (1,935/25,948) of
104 males, and 4.4% (1,980/44,569) of females tested were positive. There was a statistically significant
105 difference in these proportions ($z = 16.8595$, $p < 0.01$, calculated with Z-test). The difference
106 appeared to decrease towards the end of the study period (Figure 4).

107 **Discussion**

108 By 30 June 2020, 80.2% of all tests performed, and 77.3% of new positive cases detected within the
109 Hospital District of Helsinki and Uusimaa were analysed in HUSLAB [7], rendering our
110 surveillance data representative of Greater Helsinki. In Finland, COVID-19 has mostly affected the
111 Greater Helsinki area, which represents 30% of the Finnish population [2]. Indeed, 73% of the
112 positive cases in Finland by the end of June 2020 have been detected in Greater Helsinki [7].

113 While the number of test positive cases was similar in males and females, the positivity rate in
114 males was significantly higher than in females in our study. This may, to a small degree, be
115 explained by the overrepresentation of healthcare workers and female predominance in the elderly.
116 However, our data suggest that men pursued SARS-CoV-2 testing much less frequently than
117 women. Consequently, a subset of COVID-19 infections in men may have gone undetected.
118 Abundant evidence shows that women generally seek more health care services than men [8,9].

119 The proportion of young adults in positive cases increased towards the end of the study period,
120 which may suggest their returning back to social behaviour with risk of infection. Extension of
121 testing criteria into mild symptoms may have also contributed. Some of the restrictions imposed due
122 to COVID-19 in Finland were lowered on 1 June, including opening of restaurants [10]. However,
123 considering the incubation period [11], it does not appear likely that relaxing restrictions played a
124 role with this observation.

125 The high incidence rate observed in the elderly is in line with earlier reports [12]. Vigilance in the
126 infection control in long-term care facilities remains critically important in the mitigation of the
127 pandemic.

128 As to limitations, our data did not include all tests analysed in Greater Helsinki. No clinical data
129 were available. A bias may have been introduced by the restricted sampling criteria during March
130 2020. During the first weeks, control swabs were recommended for the positive cases – a policy
131 since abandoned. Also, during the first two weeks of April less preferred oropharyngeal swabs were
132 used due to the global shortage of nasopharyngeal swabs, which may have temporarily influenced
133 the overall test sensitivity.

134 Large dips in testing frequency were observed on every weekend, and also during public holidays
135 (Figure 1). Simultaneously, the number of new positive cases dropped each time, and the epicurve
136 (Figure 1b) may suggest that this testing deficit was not fully compensated during the following
137 weekdays.

138 In a response to need for large-scale testing, HUSLAB switched from two-shift work into a three-
139 shift work on 23 March, and personnel was reallocated. A laboratory-developed test [3] was ready
140 in use in mid-January, and testing on the cobas® 6800 system late March. Through constant global
141 shortages on reagents and plasticware, the need to deploy several independent methods was evident

142 to secure laboratory services and capacity building. The Amplidiag® COVID-19 tests were
143 deployed as of mid-April, and the Novodiag® sample-to-answer test as of mid-May.

144 In preparation for the potential next epidemic waves of COVID-19 pandemic, the difference in
145 health-care seeking behaviours between men and women needs to be accounted for to facilitate high
146 universal testing frequency. This is particularly relevant as men are at higher risk of fatal infection
147 [13], more likely to be hospitalised [14] and admitted to ICU [15] due to COVID-19. In addition,
148 advocating and maintaining social behaviours that reduce risk of infection remains a key measure of
149 mitigation in all age groups.

150 References

- 151 1. World Health Organization (14 April 2020). Strategic preparedness and response plan.
152 Retrieved from [https://www.who.int/publications/i/item/strategic-preparedness-and-
154 response-plan-for-the-new-coronavirus](https://www.who.int/publications/i/item/strategic-preparedness-and-
153 response-plan-for-the-new-coronavirus)
- 154 2. Official Statistics of Finland (OSF): Population structure [e-publication]. ISSN=1797-5395.
155 Helsinki: Statistics Finland [referred: 28.6.2020]. Access method:
156 http://www.stat.fi/til/vaerak/index_en.html. Accessed 27 June 2020.
- 157 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of
158 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3).
- 159 4. Mannonen L, Kallio-Kokko H, Loginov R, Jääskeläinen A, Jokela P, Antikainen J, et al.
160 Comparison of two commercial platforms and a laboratory developed test for detection of
161 SARS-CoV RNA. Manuscript submitted.
- 162 5. Jokela P, Jääskeläinen AE, Jarva H, Holma T, Ahava MJ, Mannonen L, et al. SARS-CoV-2
163 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation
164 and utility. Manuscript submitted.
- 165 6. Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N et al. Serological and
166 molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to
167 February 2020. Euro Surveill 2020;25(11):2000266.
- 168 7. National Institute for Health and Welfare, THL. National Infectious Disease Register.
169 Retrieved from:
170 https://sampon.thl.fi/pivot/prod/fi/epirapo/covid19case/fact_epirapo_covid19case
- 171 8. Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J. Consultation
172 length in general practice: cross sectional study in six European countries. BMJ.
173 2002;325(7362):472.

197 FIGURE LEGENDS

198 Figure 1. A) The number of SARS-CoV-2 RT-PCR tests conducted in HUSLAB by date of
199 sampling, between 1 March and 15 June, 2020. B) The number of SARS-CoV-2 positive cases
200 (columns) with seven-day central moving average (line) by date of sampling, between 1 March and
201 15 June, 2020.

202 Figure 2. A) The number of individuals tested for SARS-CoV-2 RT-PCR by age group (columns)
203 and the proportion of SARS-CoV-2 positive cases (line). B) The number of SARS-CoV-2 positive
204 cases by age group. C) Age stratification of SARS-CoV-2 positive cases by calendar week of 2020.
205 The proportion (%) of each age group is shown. D) Age-specific incidence/100,000 population of
206 SARS-CoV-2 in the Greater Helsinki area; data from the National Infectious Diseases Registry.

207 Figure 3. A-C) The age-specific number of individuals tested for SARS-CoV-2 RT-PCR by
208 calendar week of 2020. D-F) The age-specific number of SARS-CoV-2 positive cases by calendar
209 week of 2020. G-I) The age-specific proportion (%) of SARS-CoV-2 positive cases by calendar
210 week of 2020. The age range for all tested males was 1 d – 102 years (mean 43.1 and median 41
211 years) and for positive males 2 months – 97 years (mean 43.5 and median 41 years). The age range
212 for all tested females was 0 d – 106 years (mean 45.5 and median 43 years) and for positive females
213 1 month – 100 years (mean 47.7 and median 45 years).


214 Figure 4. A) The sex-specific number of SARS-CoV-2 individuals tested for SARS-CoV RT-PCR
215 by calendar week of 2020. B) The sex-specific number of SARS-CoV-2 positive cases by calendar
216 week of 2020. C) The sex-specific proportion (%) of SARS-CoV-2 positive cases by calendar week
217 of 2020.

218

219

220

Figure 1



221

222

223

224

225

226

227


228

229

230

231

Figure 2



232

233

Figure 3





Figure 4



235
236
237
238